Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AV650 in Spasticity Due to Spinal Cord Injury
NCT00531466Phase 2Terminated
- Sponsor
- Avigen
- Start
- Sep 2007
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of tolperisone in spasticity, sponsored by Avigen. Primary endpoints: Safety and Tolerability of AV650 at 1 month and Pharmacokinetics of AV650 at 1 month. Started Sep 2007; status: terminated.
02
Drugs
tolperisone
03
Conditions
spasticity
Beyond the preview
Go deeper on NCT00531466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00531466.